The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy

Journal of Orthopaedic Research

Volumn 29, Issue 4, 2011, Pages 623-632

  Sampson, Erik R ^a   Amin, Vinit ^a   Schwarz, Edward M ^a   O'Keefe, Regis J ^a   Rosier, Randy N ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Histone deacetylase inhibitor; Soft tissue sarcoma; Vorinostat; Xenograft

Indexed keywords

CASPASE 3; DOXORUBICIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; FIBROSARCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEIOMYOSARCOMA; LIPOSARCOMA; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SARCOMA CELL; SOFT TISSUE SARCOMA; STAINING; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FIBROBLASTS; FIBROSARCOMA; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, NUDE; SOFT TISSUE NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79951904594     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21274     Document Type: Article

References (47)

1. Clark MA, Fisher C, Judson I, et al. 2005. Soft-tissue sarcomas in adults. N Engl J Med 353:701-711. (Pubitemid 41175678)
2. Jemal A, Siegel R, Ward E, et al. 2009. Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
3. Wunder JS, Nielsen To, Maki RG, et al. 2007. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 8:513-524. (Pubitemid 46823060)
4. Weitz J, Antonescu CR, Brennan MF. 2003. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol 21:2719-2725. (Pubitemid 46606317)
5. Blay JY, Glabbeke M, Verweij J, et al. 2003. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 39:64-69. (Pubitemid 36005426)
6. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70. (Pubitemid 30046295)
7. Bolden JE, Peart MJ, Johnstone RW. 2006. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784. (Pubitemid 44348499)
8. Lin RJ, Evans RM. 2000. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 5:821-830.
9. Iizuka M, Smith MM. 2003. Functional consequences of histone modifications. Curr Opin Genet Dev 13:154-160. (Pubitemid 36369739)
10. Heerdt BG, Houston MA, Augenlicht LH. 1994. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res 54:3288-3293.
11. Gottlicher M, Minucci S, Zhu P, et al. 2001. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978. (Pubitemid 34062289)
12. Butler LM, Agus DB, Scher HI, et al. 2000. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165-5170.
13. Luong QT, O'Kelly J, Braunstein GD, et al. 2006. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 12:5570-5577. (Pubitemid 44497275)
14. Imai T, Adachi S, Nishijo k, et al. 2003. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene 22:9231-9242.
15. Hrzenjak A, Moinfar F, Kremser ML, et al. 2006. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 5:2203-2210. (Pubitemid 44530456)
16. Marks PA, Breslow R. 2007. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25:84-90. (Pubitemid 46087907)
17. Butler LM, Zhou X, Xu WS, et al. 2002. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99:11700-11705. (Pubitemid 34994462)
18. Kim MS, Blake M, Baek JH, et al. 2003. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291-7300. (Pubitemid 37413470)
19. Marchion DC, Bicaku E, Turner JG, et al. 2005. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res 11:8467-8475. (Pubitemid 41746962)
20. Wittenburg LA, Bisson L, Rose BJ, et al. 2010. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother Pharmacol. Bisson (in press).
21. Ellis L, Pan Y, Smyth GK, et al. 2008. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14:4500-4510.
22. Piekarz RL, Frye R, Tuner M, et al. 2009. Phase II multiinstitutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27:5410-5417.
23. Gore L, Rothenberg ML, O'Bryant CL, et al. 2008. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 14:4517-4525.
24. Gilbert J, Baker SD, Bowling MK, et al. 2001. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7:2292-2300. (Pubitemid 32751627)
25. Olsen EA, Kim YH, Kuzel TM, et al. 2007. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109-3115. (Pubitemid 47218059)
26. Kelly WK, O'Connor OA, Krug LM, et al. 2005. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931. (Pubitemid 46218695)
27. Kelly WK, Richon VM, O'Connor O, et al. 2003. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578-3588. (Pubitemid 37169221)
28. Kuendgen A, Schmid M, Schlenk R, et al. 2006. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106:112-119. (Pubitemid 43032555)
29. Pauer LR, Olivares J, Cunningham C, et al. 2004. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest 22:886-896. (Pubitemid 39665354)
30. Munster PN, Marchion D, Thomas S, et al. 2009. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res 15:7077-7084.
31. O'Connor OA, Heaney ML, Schwartz L, et al. 2006. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24:166-173. (Pubitemid 46630509)
32. Sonnemann J, Dreyer L, Hartwig M, et al. 2007. Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. J Cancer Res Clin Oncol 133:847-858. (Pubitemid 350218911)
33. Yamamoto S, Tanaka K, Sakimura R, et al. 2008. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res 28:1585-1591. (Pubitemid 351892934)
34. Hrzenjak A, Kremser ML, Strohmeier B, et al. 2008. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol 216:495-504.
35. Kutko MC, Glick RD, Butler LM, et al. 2003. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res 9:5749-5755. (Pubitemid 37499499)
36. Muhlenberg T, Zhang Y, Wagner AJ, et al. 2009. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res 69:6941-6950.
37. Kim DH, Lee J, Kim KN, et al. 2007. Anti-tumor activity of Nhydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun 356:233-238. (Pubitemid 46413153)
38. Ungerstedt JS, Sowa Y, Xu WS, et al. 2005. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102:673-678. (Pubitemid 40282724)
39. Marks P, Rifkind RA, Richon VM, et al. 2001. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194-202. (Pubitemid 33741894)
40. Ren W, Korchin B, Zhu QS, et al. 2008. Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo. Clin Cancer Res 14:2785-2795.
41. Ren W, Korchin B, Lahat G, et al. 2008. Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. Clin Cancer Res 14:5466-5475.
42. Zhang L, Hannay JA, Liu J, et al. 2006. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Res 66:8770-8778. (Pubitemid 44449194)
43. Zhan M, Yu D, Lang A, et al. 2001. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by downregulating multidrug resistance-1 expression. Cancer 92:1556-1566. (Pubitemid 32947842)
44. Hannay JA, Liu J, Zhu QS, et al. 2007. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther 6:1650-1660. (Pubitemid 46954032)
45. Zhu QS, Ren W, Korchin B, et al. 2008. Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. Cancer Res 68:2895-2903. (Pubitemid 351556289)
46. Fantin VR, Richon VM. 2007. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 13:7237-7242.
47. Louis M, Rosato RR, Battaglia E, et al. 2005. Modulation of sensitivity to doxorubicin by the histone deacetylase inhibitor sodium butyrate in breast cancer cells. Int J Oncol 26:1569-1574.